| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms, Unknown Primary | 26 | 2023 | 192 | 7.350 |
Why?
|
| Pancreatic Neoplasms | 109 | 2023 | 5061 | 5.580 |
Why?
|
| Carcinoma, Pancreatic Ductal | 43 | 2023 | 1724 | 3.450 |
Why?
|
| Adenocarcinoma | 60 | 2023 | 7789 | 2.700 |
Why?
|
| Pancreatectomy | 20 | 2021 | 652 | 1.900 |
Why?
|
| Pancreaticoduodenectomy | 32 | 2020 | 690 | 1.840 |
Why?
|
| Common Bile Duct Neoplasms | 11 | 2017 | 145 | 1.840 |
Why?
|
| Deoxycytidine | 35 | 2022 | 1353 | 1.810 |
Why?
|
| Ampulla of Vater | 10 | 2017 | 155 | 1.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 45 | 2022 | 15862 | 1.360 |
Why?
|
| Neoadjuvant Therapy | 44 | 2023 | 4975 | 1.310 |
Why?
|
| Gene Expression Profiling | 14 | 2023 | 5159 | 1.220 |
Why?
|
| Biomarkers, Tumor | 28 | 2021 | 10331 | 1.050 |
Why?
|
| Carcinoma | 7 | 2013 | 2578 | 0.950 |
Why?
|
| Albumins | 7 | 2022 | 258 | 0.900 |
Why?
|
| Preoperative Care | 10 | 2021 | 1529 | 0.880 |
Why?
|
| Precision Medicine | 5 | 2019 | 1154 | 0.810 |
Why?
|
| Paclitaxel | 10 | 2022 | 1996 | 0.760 |
Why?
|
| Pancreas | 7 | 2015 | 718 | 0.700 |
Why?
|
| Aged | 101 | 2021 | 70117 | 0.680 |
Why?
|
| Humans | 167 | 2023 | 261506 | 0.670 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2021 | 7551 | 0.650 |
Why?
|
| Male | 117 | 2022 | 123000 | 0.640 |
Why?
|
| Neoplasm Staging | 34 | 2021 | 13658 | 0.630 |
Why?
|
| Aged, 80 and over | 60 | 2021 | 29902 | 0.630 |
Why?
|
| Middle Aged | 101 | 2021 | 86204 | 0.620 |
Why?
|
| Female | 117 | 2022 | 141928 | 0.600 |
Why?
|
| Adult | 84 | 2022 | 77950 | 0.580 |
Why?
|
| Combined Modality Therapy | 28 | 2019 | 8865 | 0.570 |
Why?
|
| Peritoneal Neoplasms | 2 | 2021 | 821 | 0.560 |
Why?
|
| Diagnostic Imaging | 6 | 2017 | 1162 | 0.550 |
Why?
|
| Chemoradiotherapy | 12 | 2018 | 1946 | 0.550 |
Why?
|
| Prognosis | 40 | 2021 | 21713 | 0.530 |
Why?
|
| Kaplan-Meier Estimate | 25 | 2021 | 6207 | 0.510 |
Why?
|
| Intestinal Neoplasms | 4 | 2018 | 189 | 0.480 |
Why?
|
| Organoplatinum Compounds | 6 | 2016 | 702 | 0.480 |
Why?
|
| Immunohistochemistry | 11 | 2019 | 7548 | 0.450 |
Why?
|
| Fluorouracil | 18 | 2021 | 1944 | 0.440 |
Why?
|
| Intestine, Small | 4 | 2018 | 499 | 0.430 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2017 | 10035 | 0.430 |
Why?
|
| Antineoplastic Agents | 22 | 2021 | 14289 | 0.430 |
Why?
|
| Chemoradiotherapy, Adjuvant | 8 | 2016 | 565 | 0.420 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2013 | 600 | 0.400 |
Why?
|
| Chemotherapy, Adjuvant | 22 | 2020 | 3890 | 0.380 |
Why?
|
| Neoplasm Proteins | 4 | 2018 | 3230 | 0.370 |
Why?
|
| Watchful Waiting | 1 | 2012 | 289 | 0.370 |
Why?
|
| Treatment Outcome | 37 | 2022 | 32848 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 2330 | 0.360 |
Why?
|
| Retrospective Studies | 42 | 2021 | 37905 | 0.350 |
Why?
|
| Survival Rate | 24 | 2020 | 12221 | 0.350 |
Why?
|
| Capecitabine | 13 | 2022 | 388 | 0.340 |
Why?
|
| Mesenteric Artery, Superior | 3 | 2015 | 71 | 0.330 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2019 | 992 | 0.330 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2022 | 665 | 0.330 |
Why?
|
| Disease-Free Survival | 24 | 2020 | 10001 | 0.320 |
Why?
|
| Exosomes | 4 | 2018 | 253 | 0.320 |
Why?
|
| CA-19-9 Antigen | 5 | 2020 | 144 | 0.310 |
Why?
|
| Radiotherapy, Adjuvant | 15 | 2013 | 2231 | 0.310 |
Why?
|
| Survival Analysis | 16 | 2020 | 9180 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2015 | 8873 | 0.300 |
Why?
|
| Antimetabolites, Antineoplastic | 8 | 2020 | 1299 | 0.290 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 14889 | 0.290 |
Why?
|
| Receptors, Somatomedin | 2 | 2018 | 70 | 0.290 |
Why?
|
| Rare Diseases | 2 | 2020 | 351 | 0.290 |
Why?
|
| Lung Neoplasms | 5 | 2021 | 11538 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 8 | 2019 | 3981 | 0.280 |
Why?
|
| Colonic Neoplasms | 2 | 2018 | 1390 | 0.270 |
Why?
|
| Neoplasm Metastasis | 14 | 2018 | 5112 | 0.270 |
Why?
|
| Cohort Studies | 11 | 2021 | 9244 | 0.270 |
Why?
|
| Predictive Value of Tests | 11 | 2021 | 4892 | 0.260 |
Why?
|
| Stomach Neoplasms | 3 | 2011 | 2278 | 0.250 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 1022 | 0.250 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2021 | 973 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 2594 | 0.250 |
Why?
|
| Erlotinib Hydrochloride | 5 | 2018 | 388 | 0.240 |
Why?
|
| Cisplatin | 7 | 2019 | 2432 | 0.230 |
Why?
|
| CDX2 Transcription Factor | 3 | 2015 | 37 | 0.230 |
Why?
|
| Multivariate Analysis | 9 | 2021 | 4298 | 0.230 |
Why?
|
| Postoperative Care | 3 | 2020 | 739 | 0.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5319 | 0.220 |
Why?
|
| Prospective Studies | 14 | 2023 | 12873 | 0.220 |
Why?
|
| Homeodomain Proteins | 3 | 2015 | 1143 | 0.220 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2018 | 1331 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 5 | 2013 | 945 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 3639 | 0.210 |
Why?
|
| Antineoplastic Protocols | 1 | 2022 | 33 | 0.210 |
Why?
|
| Keratin-20 | 2 | 2013 | 44 | 0.200 |
Why?
|
| Lymphatic Metastasis | 13 | 2020 | 4844 | 0.200 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 4988 | 0.190 |
Why?
|
| Multidetector Computed Tomography | 2 | 2012 | 150 | 0.190 |
Why?
|
| CD40 Antigens | 1 | 2021 | 104 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2022 | 3251 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 1249 | 0.170 |
Why?
|
| Leucovorin | 4 | 2020 | 332 | 0.170 |
Why?
|
| Phthalazines | 1 | 2021 | 253 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 152 | 0.170 |
Why?
|
| Pneumothorax | 1 | 2000 | 153 | 0.170 |
Why?
|
| Carboplatin | 2 | 2018 | 823 | 0.170 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2019 | 92 | 0.170 |
Why?
|
| Trifluridine | 2 | 2008 | 30 | 0.160 |
Why?
|
| Uracil | 2 | 2008 | 64 | 0.160 |
Why?
|
| Time Factors | 14 | 2021 | 12926 | 0.160 |
Why?
|
| B7 Antigens | 1 | 2019 | 84 | 0.160 |
Why?
|
| Carcinosarcoma | 1 | 2019 | 146 | 0.160 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 164 | 0.160 |
Why?
|
| Biopsy | 4 | 2018 | 3443 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2013 | 226 | 0.150 |
Why?
|
| Immunotherapy | 3 | 2020 | 3341 | 0.150 |
Why?
|
| Radiography | 4 | 2020 | 1904 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2011 | 2947 | 0.150 |
Why?
|
| Neoplasms | 8 | 2020 | 15193 | 0.150 |
Why?
|
| Forecasting | 2 | 2019 | 694 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2021 | 479 | 0.150 |
Why?
|
| Pancreatic Ducts | 1 | 2018 | 122 | 0.150 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2017 | 69 | 0.150 |
Why?
|
| Carcinoma, Ductal | 1 | 2018 | 145 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 5539 | 0.150 |
Why?
|
| Argininosuccinate Synthase | 1 | 2017 | 54 | 0.150 |
Why?
|
| Cytotoxins | 1 | 2016 | 66 | 0.140 |
Why?
|
| Lymph Nodes | 3 | 2021 | 2967 | 0.140 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 221 | 0.140 |
Why?
|
| Medical Oncology | 2 | 2018 | 1423 | 0.140 |
Why?
|
| DNA, Neoplasm | 3 | 2017 | 1910 | 0.140 |
Why?
|
| Feasibility Studies | 4 | 2023 | 2292 | 0.140 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 607 | 0.140 |
Why?
|
| Mesothelioma | 1 | 2021 | 544 | 0.140 |
Why?
|
| Pancreatic Fistula | 1 | 2016 | 99 | 0.140 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 324 | 0.130 |
Why?
|
| Duodenal Neoplasms | 2 | 2013 | 138 | 0.130 |
Why?
|
| Circulating Tumor DNA | 1 | 2018 | 235 | 0.130 |
Why?
|
| Cachexia | 1 | 2017 | 161 | 0.130 |
Why?
|
| DNA Mutational Analysis | 5 | 2018 | 2283 | 0.130 |
Why?
|
| Mucin-1 | 1 | 2015 | 127 | 0.130 |
Why?
|
| Induction Chemotherapy | 4 | 2022 | 669 | 0.120 |
Why?
|
| Bevacizumab | 5 | 2021 | 938 | 0.120 |
Why?
|
| Maximum Tolerated Dose | 5 | 2018 | 1290 | 0.120 |
Why?
|
| Lymphopenia | 1 | 2016 | 199 | 0.120 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2015 | 82 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1046 | 0.120 |
Why?
|
| Spleen | 1 | 2016 | 676 | 0.120 |
Why?
|
| Patient Selection | 5 | 2011 | 2055 | 0.120 |
Why?
|
| Neoplasm Grading | 5 | 2018 | 1742 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 1 | 2019 | 493 | 0.120 |
Why?
|
| Portal Vein | 2 | 2013 | 355 | 0.120 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 4744 | 0.120 |
Why?
|
| Thrombocytosis | 1 | 2015 | 121 | 0.120 |
Why?
|
| Clinical Trials as Topic | 5 | 2014 | 3719 | 0.120 |
Why?
|
| Disease Progression | 7 | 2021 | 6682 | 0.120 |
Why?
|
| Organs at Risk | 1 | 2016 | 514 | 0.120 |
Why?
|
| Tumor Burden | 5 | 2018 | 1987 | 0.110 |
Why?
|
| Young Adult | 8 | 2020 | 21445 | 0.110 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2013 | 84 | 0.110 |
Why?
|
| Sarcopenia | 1 | 2014 | 110 | 0.110 |
Why?
|
| Mesenteric Veins | 1 | 2013 | 73 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2018 | 621 | 0.110 |
Why?
|
| BRCA1 Protein | 3 | 2021 | 493 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.110 |
Why?
|
| Texas | 6 | 2020 | 6311 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2008 | 4638 | 0.100 |
Why?
|
| Radiotherapy | 3 | 2008 | 1824 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 2403 | 0.100 |
Why?
|
| Cytogenetics | 1 | 2011 | 149 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2005 | 3168 | 0.100 |
Why?
|
| Cyclin D1 | 1 | 2014 | 576 | 0.100 |
Why?
|
| Melanoma | 2 | 2019 | 5317 | 0.100 |
Why?
|
| Quinazolines | 3 | 2013 | 923 | 0.100 |
Why?
|
| Bile | 1 | 2011 | 81 | 0.100 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 799 | 0.100 |
Why?
|
| Colorectal Neoplasms | 2 | 2008 | 3578 | 0.100 |
Why?
|
| Blood Chemical Analysis | 1 | 2011 | 118 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 4 | 2018 | 4367 | 0.100 |
Why?
|
| Jaundice, Obstructive | 1 | 2010 | 16 | 0.100 |
Why?
|
| Medical History Taking | 2 | 2018 | 173 | 0.100 |
Why?
|
| Decision Trees | 1 | 2011 | 178 | 0.100 |
Why?
|
| Exercise | 1 | 2018 | 1183 | 0.100 |
Why?
|
| Decision Support Techniques | 2 | 2013 | 622 | 0.090 |
Why?
|
| Survival | 2 | 2013 | 177 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 550 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 669 | 0.090 |
Why?
|
| United States | 5 | 2021 | 15433 | 0.090 |
Why?
|
| Carcinoid Tumor | 1 | 2012 | 280 | 0.090 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2012 | 330 | 0.090 |
Why?
|
| Smad4 Protein | 1 | 2011 | 196 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 590 | 0.090 |
Why?
|
| Radiotherapy, Conformal | 2 | 2016 | 902 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2016 | 1171 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 487 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2016 | 2104 | 0.090 |
Why?
|
| Risk Factors | 10 | 2018 | 17523 | 0.090 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 1656 | 0.090 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 189 | 0.090 |
Why?
|
| Isoflavones | 1 | 2010 | 72 | 0.090 |
Why?
|
| Inflammation | 2 | 2017 | 2522 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2013 | 627 | 0.090 |
Why?
|
| Abdominal Neoplasms | 1 | 2011 | 231 | 0.090 |
Why?
|
| Mutation | 6 | 2018 | 15179 | 0.090 |
Why?
|
| Cholestasis | 1 | 2011 | 203 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 1258 | 0.080 |
Why?
|
| Radiotherapy Dosage | 6 | 2016 | 3842 | 0.080 |
Why?
|
| ErbB Receptors | 2 | 2015 | 2295 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 1870 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 6009 | 0.080 |
Why?
|
| Laparoscopy | 1 | 2018 | 1225 | 0.080 |
Why?
|
| Drainage | 1 | 2011 | 416 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2992 | 0.080 |
Why?
|
| Keratin-7 | 1 | 2008 | 52 | 0.080 |
Why?
|
| Palliative Care | 2 | 2018 | 2037 | 0.080 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 2173 | 0.080 |
Why?
|
| Preoperative Period | 2 | 2020 | 344 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2017 | 1763 | 0.080 |
Why?
|
| Cytokines | 1 | 2017 | 2809 | 0.080 |
Why?
|
| Liquid Biopsy | 2 | 2018 | 158 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2014 | 1863 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2011 | 889 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 598 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2023 | 2291 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2007 | 217 | 0.070 |
Why?
|
| Medical Records | 1 | 2008 | 415 | 0.070 |
Why?
|
| Liver Neoplasms | 2 | 2013 | 4557 | 0.070 |
Why?
|
| Models, Biological | 2 | 2014 | 3254 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2015 | 1323 | 0.070 |
Why?
|
| Drug Administration Schedule | 5 | 2011 | 3472 | 0.070 |
Why?
|
| Lactoferrin | 1 | 2006 | 81 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2008 | 414 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 4549 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2019 | 1391 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2012 | 2218 | 0.060 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2018 | 347 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2011 | 2927 | 0.060 |
Why?
|
| Stents | 1 | 2011 | 1096 | 0.060 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 2864 | 0.060 |
Why?
|
| Radiography, Thoracic | 2 | 2013 | 462 | 0.060 |
Why?
|
| Algorithms | 3 | 2018 | 3890 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2011 | 882 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 5437 | 0.060 |
Why?
|
| DNA Adducts | 2 | 2014 | 210 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 1546 | 0.060 |
Why?
|
| Camptothecin | 1 | 2005 | 517 | 0.060 |
Why?
|
| Laparotomy | 1 | 2004 | 211 | 0.060 |
Why?
|
| Age Factors | 3 | 2018 | 5377 | 0.060 |
Why?
|
| Patient Readmission | 2 | 2018 | 548 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2016 | 5542 | 0.050 |
Why?
|
| Physical Examination | 1 | 2004 | 299 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 4654 | 0.050 |
Why?
|
| Disease Management | 1 | 2007 | 1052 | 0.050 |
Why?
|
| Esophagogastric Junction | 1 | 2005 | 543 | 0.050 |
Why?
|
| Adolescent | 4 | 2016 | 31252 | 0.050 |
Why?
|
| Phosphorylation | 3 | 2019 | 4804 | 0.050 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2021 | 67 | 0.050 |
Why?
|
| Neurons | 1 | 2012 | 2287 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2021 | 254 | 0.050 |
Why?
|
| Endoscopy | 1 | 2004 | 479 | 0.050 |
Why?
|
| Quality of Life | 2 | 2013 | 4532 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 1586 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2013 | 3518 | 0.050 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2019 | 27 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1363 | 0.050 |
Why?
|
| Administration, Oral | 3 | 2008 | 1544 | 0.040 |
Why?
|
| Drug Approval | 1 | 2020 | 178 | 0.040 |
Why?
|
| Biomarkers | 2 | 2022 | 5047 | 0.040 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2019 | 159 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 333 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 335 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 7702 | 0.040 |
Why?
|
| Nomograms | 1 | 2021 | 313 | 0.040 |
Why?
|
| Vimentin | 1 | 2019 | 253 | 0.040 |
Why?
|
| Thymine | 2 | 2008 | 46 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 14551 | 0.040 |
Why?
|
| Registries | 1 | 2006 | 2170 | 0.040 |
Why?
|
| Pyrrolidines | 2 | 2008 | 113 | 0.040 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 53 | 0.040 |
Why?
|
| Antigens, Neoplasm | 2 | 2017 | 1506 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2016 | 1014 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 1021 | 0.040 |
Why?
|
| Etoposide | 1 | 2018 | 870 | 0.040 |
Why?
|
| Length of Stay | 2 | 2018 | 1900 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 268 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 342 | 0.040 |
Why?
|
| Drug Combinations | 2 | 2008 | 621 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1681 | 0.040 |
Why?
|
| Liver | 1 | 2006 | 2961 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 358 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 827 | 0.040 |
Why?
|
| Cadherins | 1 | 2019 | 660 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2018 | 380 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2018 | 285 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 15694 | 0.030 |
Why?
|
| Contrast Media | 2 | 2013 | 1472 | 0.030 |
Why?
|
| Prevalence | 2 | 2018 | 3260 | 0.030 |
Why?
|
| Breath Holding | 1 | 2015 | 44 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1945 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 4971 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 363 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 368 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 486 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 852 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 750 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2021 | 1533 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 88 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 665 | 0.030 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 1085 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 657 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 2014 | 131 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 785 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 2013 | 61 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 573 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 671 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 490 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 1688 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2013 | 68 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2014 | 134 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2015 | 760 | 0.030 |
Why?
|
| Biological Transport | 1 | 2014 | 597 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 1217 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 875 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2015 | 304 | 0.030 |
Why?
|
| DNA Damage | 1 | 2021 | 1954 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2013 | 257 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2017 | 7226 | 0.030 |
Why?
|
| Nervous System | 1 | 2013 | 165 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2010 | 2054 | 0.030 |
Why?
|
| Office Visits | 1 | 2013 | 97 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 5637 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2013 | 229 | 0.030 |
Why?
|
| Markov Chains | 1 | 2013 | 175 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 528 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 2738 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 221 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 3203 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1274 | 0.030 |
Why?
|
| Piperazines | 1 | 2021 | 2101 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 2483 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 100 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 2011 | 159 | 0.030 |
Why?
|
| Body Composition | 1 | 2014 | 595 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1048 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 1283 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2016 | 2316 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 1648 | 0.020 |
Why?
|
| Dissection | 1 | 2011 | 156 | 0.020 |
Why?
|
| Smoking | 1 | 2000 | 2440 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2013 | 501 | 0.020 |
Why?
|
| Dyspnea | 1 | 2013 | 416 | 0.020 |
Why?
|
| Proteomics | 1 | 2018 | 1380 | 0.020 |
Why?
|
| Exome | 1 | 2015 | 1239 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 583 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 2352 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 793 | 0.020 |
Why?
|
| Body Weight | 1 | 2014 | 1293 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2011 | 309 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 472 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6295 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3441 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2011 | 332 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2012 | 6869 | 0.020 |
Why?
|
| Oxaloacetates | 1 | 2008 | 7 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 1546 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2011 | 749 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1664 | 0.020 |
Why?
|
| Antibodies | 1 | 2011 | 838 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.020 |
Why?
|
| Everolimus | 1 | 2010 | 415 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 1062 | 0.020 |
Why?
|
| Sepsis | 1 | 2013 | 652 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 1382 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2013 | 674 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1493 | 0.020 |
Why?
|
| Appetite | 1 | 2007 | 73 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 242 | 0.020 |
Why?
|
| Family | 1 | 2011 | 736 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 4757 | 0.020 |
Why?
|
| Neuroendocrine Tumors | 1 | 2012 | 634 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 383 | 0.020 |
Why?
|
| Sirolimus | 1 | 2010 | 814 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2006 | 100 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5178 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2009 | 690 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2007 | 250 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2011 | 1335 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2006 | 726 | 0.020 |
Why?
|
| Nausea | 1 | 2007 | 525 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 2508 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 3569 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 1375 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2011 | 806 | 0.010 |
Why?
|
| Research Design | 1 | 2011 | 1544 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2013 | 6100 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 2007 | 348 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 589 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2009 | 795 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2007 | 2307 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2010 | 1549 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 3552 | 0.010 |
Why?
|
| Fatigue | 1 | 2007 | 1239 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 4938 | 0.010 |
Why?
|
| Pain | 1 | 2007 | 1658 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2006 | 1248 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 11965 | 0.010 |
Why?
|
| Child | 1 | 2011 | 29154 | 0.010 |
Why?
|